Stock Events

Stock Events

Altamira Therapeutics 

$0.05
56
+$0+4.2% Wednesday 17:35

Statistics

Day High
0.05
Day Low
0.05
52W High
0.15
52W Low
0.05
Volume
23
Avg. Volume
3,913
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

15AprExpected
Q4 0
Q2 2024
Q1 2025
Q2 2025
Next
-2.38
-1.77
-1.15
-0.54
Expected EPS
-0.647709979
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
0Revenue
-16.92MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow CYTOF. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Vertex Pharmaceuticals
VRTX
Mkt Cap109.11B
Vertex Pharmaceuticals is a competitor because it also focuses on developing treatments for serious genetic diseases, potentially overlapping with Altamira's therapeutic areas.
Gilead Sciences
GILD
Mkt Cap148.78B
Gilead Sciences competes in the biopharmaceutical space, developing drugs that could be in direct competition with Altamira's offerings for various diseases.
Regeneron Pharmaceuticals
REGN
Mkt Cap68.5B
Regeneron Pharmaceuticals is known for its innovation in biotechnology, potentially competing with Altamira in developing therapies for similar conditions.
AMGEN
AMGN
Mkt Cap160.66B
Amgen is a biotech giant that develops novel therapies for serious illnesses, which could directly compete with Altamira's product pipeline.
Biogen
BIIB
Mkt Cap22.63B
Biogen focuses on developing therapies for neurological diseases, a space where Altamira could also be making strides, making them competitors.
Alnylam Pharmaceuticals
ALNY
Mkt Cap60.25B
Alnylam Pharmaceuticals works on RNAi therapeutics, a cutting-edge area of medicine that could overlap with Altamira's research interests.
Ionis Pharmaceuticals
IONS
Mkt Cap12.03B
Ionis Pharmaceuticals is a leader in RNA-targeted drug discovery and development, potentially competing with Altamira in genetic disease treatments.
CRISPR Therapeutics
CRSP
Mkt Cap5.82B
CRISPR Therapeutics is at the forefront of gene editing, a technology that could be used to develop treatments in the same domains as Altamira.

About

Altamira Therapeutics Ltd. engages in developing therapeutics that address various unmet medical needs. Its commercial products include Bentrio, a drug-free nasal spray for personal protection against airborne viruses and allergens. The company is also involved in the development of RNA therapeutics for extrahepatic therapeutic targets, including OligoPhore and SemaPhore platforms that are in preclinical stage for oligonucleotide and mRNA delivery; AM-125 that is in phase II clinical trial for the intranasal treatment of vertigo; Keyzilen, which is in phase III clinical trial for the treatment of acute inner ear tinnitus; and Sonsuvi that is in phase III of clinical development for the treatment of acute inner ear hearing loss. It operates in Switzerland, the United States, Europe, and Australia. The company was formerly known as Auris Medical Holding Ltd. and changed its name to Altamira Therapeutics Ltd. in July 2021. Altamira Therapeutics Ltd. was founded in 2003 and is headquartered in Hamilton, Bermuda.
Show more...
CEO
Employees
10
Country
BM
ISIN
BMG0360L1349

Listings

OTC Link
US
CYTOF

0 Comments

Share your thoughts

FAQ

What is Altamira Therapeutics stock price today?▼
The current price of CYTOF is $0.05 USD — it has increased by +4.2% in the past 24 hours. Watch Altamira Therapeutics stock price performance more closely on the chart.
What is Altamira Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Altamira Therapeutics stocks are traded under the ticker CYTOF.
When is the next Altamira Therapeutics earnings date?▼
Altamira Therapeutics is going to release the next earnings report on April 15, 2026.
What is Altamira Therapeutics revenue for the last year?▼
Altamira Therapeutics revenue for the last year amounts to 0 USD.
What is Altamira Therapeutics net income for the last year?▼
CYTOF net income for the last year is -16.92M USD.
How many employees does Altamira Therapeutics have?▼
As of April 02, 2026, the company has 10 employees.
In which sector is Altamira Therapeutics located?▼
Altamira Therapeutics operates in the Professional, Scientific, and Technical Services sector.
When did Altamira Therapeutics complete a stock split?▼
Altamira Therapeutics has not had any recent stock splits.